This week, the overall grades of six Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Keryx Biopharmaceuticals (NASDAQ:KERX) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Keryx Biopharmaceuticals focuses on developing and commercializing pharmaceuticals for the treatment of cancer and renal disease. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, KERX also gets F’s. As of Aug. 17, 14.7% of outstanding Keryx Biopharmaceuticals shares were held short. For a full analysis of KERX stock, visit Portfolio Grader.
Horizon Pharma Inc. (NASDAQ:HZNP) gets weaker ratings this week as last week’s C drops to a D. Horizon Pharma, Inc is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. . The stock gets F’s in Earnings Momentum, Equity, and Cash Flow. The stock price has fallen 38.4% over the past month, worse than the 5.7% increase the Nasdaq has seen over the same period of time. As of Aug. 17, 17.3% of outstanding Horizon Pharma Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of HZNP stock.
Momenta Pharmaceuticals (NASDAQ:MNTA) earns a D this week, moving down from last week’s grade of C. Momenta Pharmaceuticals is a biotechnology company. The stock gets F’s in Earnings Growth, Earnings Momentum, and Sales Growth. The price of MNTA has declined 2.6% since last month. To get an in-depth look at MNTA, get Portfolio Grader’s complete analysis of MNTA stock.
This week, Exelixis
(NASDAQ:EXEL) drops from a C to a D rating. Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock gets F’s in Earnings Momentum and Sales Growth. Share prices fell 27.6% over the past month. As of Aug. 17, 17.8% of outstanding Exelixis shares were held short. For a full analysis of EXEL stock, visit Portfolio Grader.
The rating of Sinovac Biotech (NASDAQ:SVA) slips from a C to a D. Sinovac Biotech researches, develops, manufactures, and markets various vaccines, including flu vaccines and vaccines for Hepatitis A. The stock gets F’s in Earnings Revisions and Equity. The price of SVA has dropped 0.9% from a month ago. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. To get an in-depth look at SVA, get Portfolio Grader’s complete analysis of SVA stock.
SIGA Technologies (NASDAQ:SIGA) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). SIGA Technologies is a bio-defense company engaged in the discovery, development and commercialization of products for use in defense against biological warfare agents such as smallpox and arenaviruses. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Margin Growth also get F’s. Shares of the company have dropped 4.9% from a month ago. As of Aug. 17, 14.2% of outstanding SIGA Technologies shares were held short. For more information, get Portfolio Grader’s complete analysis of SIGA stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
